Sage Therapeutics Inc. (NASDAQ:SAGE) shares saw an uptick in trading volume on Tuesday . 1,391,954 shares changed hands during trading, an increase of 65% from the previous session’s volume of 845,709 shares.The stock last traded at $37.41 and had previously closed at $42.46.

Several brokerages recently commented on SAGE. William Blair reaffirmed an “outperform” rating and set a $75.00 price target on shares of Sage Therapeutics in a research report on Friday, July 15th. JPMorgan Chase & Co. reaffirmed a “buy” rating and set a $71.00 price target on shares of Sage Therapeutics in a research report on Tuesday, July 12th. Cowen and Company reiterated a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Chardan Capital reiterated a “sell” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. Finally, BMO Capital Markets reiterated a “buy” rating on shares of Sage Therapeutics in a research note on Tuesday, July 12th. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $66.18.

The firm’s 50-day moving average is $38.36 and its 200 day moving average is $34.60. The stock’s market capitalization is $1.18 billion.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.06. Analysts anticipate that Sage Therapeutics Inc. will post ($4.34) EPS for the current fiscal year.

In related news, Director Kevin P. Starr sold 850,000 shares of the firm’s stock in a transaction that occurred on Monday, May 16th. The shares were sold at an average price of $31.25, for a total transaction of $26,562,500.00. Following the transaction, the director now owns 65,227 shares of the company’s stock, valued at $2,038,343.75. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Kimi Iguchi sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 12th. The shares were sold at an average price of $49.55, for a total transaction of $247,750.00. Following the transaction, the chief financial officer now directly owns 83,739 shares in the company, valued at approximately $4,149,267.45. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. Nationwide Fund Advisors raised its position in shares of Sage Therapeutics by 9.4% in the fourth quarter. Nationwide Fund Advisors now owns 21,143 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 1,816 shares during the last quarter. California State Teachers Retirement System raised its position in shares of Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock valued at $1,491,000 after buying an additional 400 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Sage Therapeutics during the fourth quarter valued at $1,870,000. Jennison Associates LLC acquired a new position in shares of Sage Therapeutics during the fourth quarter valued at $14,875,000. Finally, RS Investment Management Co. LLC raised its position in shares of Sage Therapeutics by 14.7% in the fourth quarter. RS Investment Management Co. LLC now owns 504,405 shares of the biopharmaceutical company’s stock valued at $29,407,000 after buying an additional 64,567 shares during the last quarter.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.